<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2075">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05422885</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00053594</org_study_id>
    <nct_id>NCT05422885</nct_id>
  </id_info>
  <brief_title>Safety and Feasibility of Dasatinib and Quercetin in Adults at Risk for Alzheimer's Disease</brief_title>
  <acronym>STAMINA</acronym>
  <official_title>Senolytics To Alleviate Mobility Issues and Neurological Impairment in Aging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lew Lipsitz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hebrew SeniorLife</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this pilot study is to demonstrate the safety and feasibility of administering&#xD;
      intermittent doses of Dasatinib and Quercetin (D+Q) in older adults at risk of Alzheimer's&#xD;
      disease (AD). The study will evaluate whether giving D+Q may improve cerebral blood flow&#xD;
      regulation, mobility, and cognition in older adults, and thus may prevent progression to&#xD;
      Alzheimer's disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will conduct a 12-week single arm, open label, pre-post pilot study in 12&#xD;
      adults aged 65 or older with slow gait speed (&lt;1.0 m/sec) and Mild Cognitive Impairment (MCI,&#xD;
      defined as a Telephone Montreal Cognitive Assessment Score (MoCA) &lt;19). Participants will be&#xD;
      asked to take 100mg of Dasatinib and 1,250mg of Quercetin for 2 consecutive days, every two&#xD;
      weeks over a period of 12 weeks (12 doses in total, given over 6 cycles).&#xD;
&#xD;
      At baseline, enrolled participants will undergo gait speed and neurocognitive testing, and&#xD;
      provide blood and urine to evaluate biomarkers of senescence. At visits 3,4, 6, and 7,&#xD;
      participants will have safety labs drawn, and the study team will assess medication adherence&#xD;
      and adverse events. At visits 2, 5, and 8, participants will undergo cognitive assessments,&#xD;
      gait speed testing, cerebral blood flow and neurovascular coupling testing. At the final&#xD;
      study visit, participants will again provide blood and urine to assess biomarkers of&#xD;
      senescence.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 20, 2022</start_date>
  <completion_date type="Anticipated">June 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neurovascular coupling</measure>
    <time_frame>Screening, 8, and 14 weeks</time_frame>
    <description>Change in cerebral blood flow during an N-back cognitive task using transcranial doppler ultrasound.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Executive function</measure>
    <time_frame>Baseline, 8, and 14 weeks</time_frame>
    <description>Assess change in executive cognitive function using TRAILS test, corrected for response time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gait speed</measure>
    <time_frame>Screening, 8, and 14 weeks</time_frame>
    <description>Assess change in gait speed. Performed without a distracting cognitive task.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physical performance</measure>
    <time_frame>Baseline, 8, and 14 weeks</time_frame>
    <description>Assessment of overall physical function using the short physical performance battery (SPPB) scored from 0-12, based on a composite of balance, strength, and walking speed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mobility</measure>
    <time_frame>Baseline, 8, and 14 weeks</time_frame>
    <description>Test of mobility using timed up and go test, including standing from a chair, walking, and turning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grip strength</measure>
    <time_frame>Baseline, 8, and 14 weeks</time_frame>
    <description>Measure of grip strength using a hand dynamometer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gait speed during cognitive task</measure>
    <time_frame>Baseline, 8, and 14 weeks</time_frame>
    <description>Measure of gait speed during a cognitive task.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Senescent CD3 cells expressing p16</measure>
    <time_frame>Screening and 14 weeks</time_frame>
    <description>Measure of the number of senescent CD3 lymphocytes in the blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SASP factors in blood and urine</measure>
    <time_frame>Screening and 14 weeks</time_frame>
    <description>Measure of the senescence-associated biomarkers IL-1alpha picogram/mL and IL-6 picogram/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SASP factors in blood and urine</measure>
    <time_frame>Screening and 14 weeks</time_frame>
    <description>Measure of the senescence-associated biomarkers MMP-9 nanograms/mL and MMP-12 nanograms/mL.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Aging</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dasatinib and Quercetin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasatinib</intervention_name>
    <description>Dasatinib 100 mg for 2 consecutive days, every two weeks for 12 weeks</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>Sprycel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quercetin</intervention_name>
    <description>Quercetin 1,250 mg for 2 consecutive days, every two weeks for 12 weeks</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ambulatory,&#xD;
&#xD;
          -  Community dwelling,&#xD;
&#xD;
          -  Slow gait speed (&lt;1 m/second),&#xD;
&#xD;
          -  Mild Cognitive Impairment (Telephone MoCA score &lt;19, which is indicative of cognitive&#xD;
             impairment)&#xD;
&#xD;
        Exclusion Criteria, or as per clinical judgment:&#xD;
&#xD;
          -  Telephone MoCA score &lt;10 points&#xD;
&#xD;
          -  Unwilling to take study medications or follow study protocol&#xD;
&#xD;
          -  Inability to independently perform Katz Activities of Daily Living (ADLs),&#xD;
&#xD;
          -  Allergies to Dasatinib or Quercetin,&#xD;
&#xD;
          -  Hospitalization within 6 months,&#xD;
&#xD;
          -  Unstable coronary artery disease (myocardial infarction within 6 months or angina),&#xD;
&#xD;
          -  Stroke or transient ischemic attack in the past 6 months,&#xD;
&#xD;
          -  Chronic heart failure,&#xD;
&#xD;
          -  Current or chronic history of liver disease,&#xD;
&#xD;
          -  Neurodegenerative disease including Parkinson's disease,&#xD;
&#xD;
          -  Anemia,&#xD;
&#xD;
          -  Chronic renal disease,&#xD;
&#xD;
          -  Drug or alcohol abuse in the last 5 years,&#xD;
&#xD;
          -  QTc prolongation,&#xD;
&#xD;
          -  Thrombocytopenia,&#xD;
&#xD;
          -  Neutropenia,&#xD;
&#xD;
          -  Prolonged prothrombin time or INR,&#xD;
&#xD;
          -  Indications of current fluid retention,&#xD;
&#xD;
          -  History or current diagnosis of pulmonary hypertension,&#xD;
&#xD;
          -  Inability to insonate the middle cerebral artery through a temporal bone window on at&#xD;
             least one side using transcranial Doppler ultrasound, or&#xD;
&#xD;
          -  Chronic use of any of the following medications: anti-arrhythmic medications,&#xD;
             antipsychotics, anxiolytics, anti-platelet or anti-coagulant medications other than&#xD;
             aspirin, quinolone antibiotics, or drugs metabolized by the same liver enzymes as&#xD;
             Quercetin or Dasatinib.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lewis Lipsitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hebrew Senior Life</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kathryn Baldyga</last_name>
    <phone>6179715380</phone>
    <email>kathrynbaldyga@hsl.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ikechukwu Iloputaife</last_name>
    <phone>6179715305</phone>
    <email>iloputaife@hsl.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hebrew Senior Life</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie Baldyga</last_name>
    </contact>
    <contact_backup>
      <last_name>Ike Iloputaife</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2022</verification_date>
  <study_first_submitted>March 14, 2022</study_first_submitted>
  <study_first_submitted_qc>June 13, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2022</study_first_posted>
  <last_update_submitted>June 13, 2022</last_update_submitted>
  <last_update_submitted_qc>June 13, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hebrew SeniorLife</investigator_affiliation>
    <investigator_full_name>Lew Lipsitz</investigator_full_name>
    <investigator_title>Director, Marcus Institute for Aging Research</investigator_title>
  </responsible_party>
  <keyword>Alzheimer's disease</keyword>
  <keyword>Senescence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dasatinib</mesh_term>
    <mesh_term>Quercetin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 9, 2022</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/85/NCT05422885/Prot_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

